Bayer AG

Bayer

<div class="infobox">
<div class="infobox-header">Bayer AG</div>
<div class="infobox-content">
<table>
<tr><th>Stock Symbol</th><td>ETR: BAYN (DAX component)</td></tr>
<tr><th>Headquarters</th><td>Leverkusen, North Rhine-Westphalia, Germany</td></tr>
<tr><th>Founded</th><td>1863 (as Bayerdyes)</td></tr>
<tr><th>Market Cap</th><td>~€65 billion (2026)</td></tr>
<tr><th>2025 Revenue</th><td>~€44 billion</td></tr>
<tr><th>Employees</th><td>~99,000</td></tr>
<tr><th>Focus Areas</th><td>Pharmaceuticals, crop science, consumer health, oncology, cardiovascular, neuroscience</td></tr>
</table>
</div>
</div>

Overview

Bayer

<div class="infobox">
<div class="infobox-header">Bayer AG</div>
<div class="infobox-content">
<table>
<tr><th>Stock Symbol</th><td>ETR: BAYN (DAX component)</td></tr>
<tr><th>Headquarters</th><td>Leverkusen, North Rhine-Westphalia, Germany</td></tr>
<tr><th>Founded</th><td>1863 (as Bayerdyes)</td></tr>
<tr><th>Market Cap</th><td>~€65 billion (2026)</td></tr>
<tr><th>2025 Revenue</th><td>~€44 billion</td></tr>
<tr><th>Employees</th><td>~99,000</td></tr>
<tr><th>Focus Areas</th><td>Pharmaceuticals, crop science, consumer health, oncology, cardiovascular, neuroscience</td></tr>
</table>
</div>
</div>

Overview

Bayer AG is a German multinational pharmaceutical and life sciences company headquartered in Leverkusen, Germany, founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott [1](https://www.bayer.com). With a history spanning over 160 years, Bayer has evolved from a dyestuff manufacturer into one of the world's largest pharmaceutical companies with significant operations in cardiovascular medicine, oncology, women's health, ophthalmology, and neuroscience. The company employs approximately 99,000 people worldwide and maintains operations in over 80 countries, with major research and development centers in Germany, the United States, and Japan [2](https://www.bayer.com/en/about-us).

Bayer's involvement in neuroscience dates back to the early 20th century, with the development of aspirin and later psychopharmaceuticals. Today, the company maintains active research programs in neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease, through both internal discovery efforts and strategic partnerships.[@neuroinflammation] The company's neuroscience strategy leverages its expertise in small molecule development, biologics, and innovative partnership models to address the significant unmet medical need in these devastating conditions.[@clinical_trials_pd]

Corporate History and Evolution

The Early Years (1863-1900)

Bayer was founded on August 21, 1863, as Dyestuff Factory Friedrich Bayer & Co. in Barmen, Germany [3](https://en.wikipedia.org/wiki/Bayer_AG). The company initially focused on synthetic dyes, a relatively new technology at the time that would revolutionize the textile industry. Friedrich Bayer, a successful businessman, and Johann Friedrich Weskott, a chemist, established the company to capitalize on the growing demand for synthetic colorants.

The company quickly established itself as a leader in the emerging field of synthetic chemistry, developing innovative dyes that competed successfully with natural alternatives. By the 1880s, Bayer had expanded its operations to include a second production facility in Leverkusen, which would later become the company's global headquarters. The strategic location along the Rhine River provided crucial advantages in terms of logistics and access to raw materials.

Expansion into Pharmaceuticals (1900-1950)

The transition from dyestuffs to pharmaceuticals began in the late 19th century, as Bayer's chemists discovered the therapeutic potential of various dye compounds. The development of acetylsalicylic acid (ASA), later marketed as Aspirin, in 1897 marked a turning point in the company's history [4](https://www.bayer.com/en/heritage). Aspirin became one of the most successful pharmaceutical products in history and remains one of the most widely used medications worldwide.

The early 20th century saw Bayer expand its pharmaceutical portfolio significantly. The company developed:

• Phenacetin (1887): An analgesic and antipyretic
• Sulfanilamide (1932): The first sulfonamide antibiotic
• Prontosil (1935): The first commercially available sulfonamide
• Metamizole (1920s): Analgesic and antipyretic

Post-War Reconstruction and Modernization (1950-2000)

Following World War II, Bayer underwent significant restructuring. The company lost its foreign subsidiaries and patents as a result of the war, requiring a fundamental rebuild of its international presence. During this period, Bayer refocused its research efforts on cardiovascular disease, oncology, and infectious diseases while maintaining its commitment to neuroscience research.

The latter half of the 20th century saw Bayer establish major research facilities in the United States and expand its global footprint. Key developments included:

• 1963: Establishment of Bayer US headquarters in Pittsburgh, Pennsylvania
• 1971: Formation of Berlex Laboratories (later Berlex Biosciences) in the US
• 1990s: Major investments in biotechnology and genomics research

The 21st Century: Strategic Transformation

The early 2000s marked a period of significant transformation for Bayer. The company divested its Crop Protection business to focus on healthcare, reorganized its pharmaceutical division, and pursued an aggressive acquisition strategy to strengthen its pipeline. The €4.4 billion acquisition of Schering AG in 2006 dramatically expanded Bayer's pharmaceutical portfolio, particularly in women's health and oncology [5](https://www.bayer.com/en/investors).

The 2020s have seen Bayer undergo further strategic evolution, including a major restructuring announced in 2024 to streamline operations and focus on pharmaceutical innovation. The company has pivoted toward advanced therapies, including gene therapies and innovative biologics, while maintaining its commitment to neuroscience research.

Research Facilities and Global R&D Network

Bayer operates a globally integrated research and development network spanning multiple continents:

European Research Infrastructure

• Leverkusen Innovation Center (Germany): The company's primary research campus, housing discovery research for pharmaceuticals, including neuroscience programs. The site includes state-of-the-art laboratories for medicinal chemistry, biology, and drug metabolism [6](https://www.bayer.com/en/research).
• Berlin Research Center: Focus on oncology and immunology research, with emerging programs in neurodegenerative diseases.
• Cambridge, UK Facility: Strategic research partnership hub, collaborating with leading academic institutions on early-stage discovery.
• Wuppertal, Germany: Manufacturing and quality control for pharmaceutical products.

North American Operations

• Boston Innovation Center (Massachusetts): Bayer's US pharmaceutical headquarters and primary research site for oncology and neuroscience. The Boston area location provides access to the world's leading biotechnology ecosystem and academic medical centers [7](https://www.bayer.com/en/usa).
• San Francisco Bay Area (California): Discovery research focused on cell and gene therapies, with partnerships in Parkinson's disease and Alzheimer's disease programs.
• Berkeley, California: Agricultural biotechnology research, with applications in pharmaceutical development.

Asia-Pacific Research

• Osaka, Japan: Regional headquarters and clinical development operations for the Asia-Pacific region.
• Shanghai, China: Clinical development and medical affairs for the Chinese market.
• Singapore: Regional hub for clinical operations and regulatory affairs.

Neuroscience Pipeline and Programs

Bayer maintains active research programs in neurodegenerative diseases, with a particular focus on Alzheimer's disease and Parkinson's disease. The company's approach combines internal discovery efforts with strategic partnerships to build a sustainable pipeline.

Alzheimer's Disease Programs

Elenbecestat (BACE Inhibitor)

Elenbecestat (formerly ASP-ND-003) is a novel beta-site amyloid precursor protein cleaving enzyme (BACE) inhibitor developed in partnership with Eisai Co., Ltd. [8](https://www.bayer.com/en/news/elebecestat). BACE is a crucial enzyme in the amyloid cascade hypothesis, responsible for cleaving amyloid precursor protein (APP) to produce amyloid-beta peptides that accumulate in the brains of Alzheimer's disease patients.

The development program for elenbecestat represented one of the most advanced BACE inhibitor programs in the industry:

• Phase 1 trials: Demonstrated dose-dependent reduction in amyloid-beta production in cerebrospinal fluid [9](https://pubmed.ncbi.nlm.nih.gov/29371425/)
• Phase 2 trials: Showed evidence of disease modification in early Alzheimer's disease patients
• Phase 3 trials: Initiated in 2019 as part of the MissionAD program

Tau-Targeting Approaches

Bayer has explored targeting tau protein pathology, which co-localizes with amyloid plaques in Alzheimer's disease and correlates with cognitive decline:

• Tau aggregation inhibitors: Research programs targeting the formation of neurofibrillary tangles
• Tau kinases inhibitors: Approaches to reduce pathological tau phosphorylation
• Tau immunotherapy: Active and passive vaccination strategies against pathological tau species [11](https://pubmed.ncbi.nlm.nih.gov/36028266/)

Neuroinflammation Modulation

Given the strong evidence for neuroinflammation in Alzheimer's disease pathogenesis, Bayer has pursued programs targeting microglial activation and neuroinflammatory pathways:

• TREM2 modulators: Targeting the triggering receptor expressed on myeloid cells 2, a key regulator of microglial function [12](https://pubmed.ncbi.nlm.nih.gov/34427915/)
• CSF1R inhibitors: Colony-stimulating factor 1 receptor inhibition to modulate microglial proliferation and activation
• NLRP3 inflammasome inhibitors: Targeting the NOD-like receptor pyrin domain containing 3 inflammasome

Parkinson's Disease Programs

Bayer has maintained a strategic interest in Parkinson's disease research, recognizing the significant unmet medical need and the company's historical expertise in movement disorders:

Alpha-Synuclein Targeting

The company has invested in programs targeting alpha-synuclein aggregation, the key pathological protein in Parkinson's disease:

• Small molecule aggregation inhibitors: Compounds designed to prevent the misfolding and aggregation of alpha-synuclein
• Monoclonal antibodies: Anti-alpha-synuclein antibodies for passive immunotherapy
• Gene therapy approaches: AAV-vector based delivery of protective genes [13](https://pubmed.ncbi.nlm.nih.gov/32861262/)

Neuroprotective Strategies

Bayer's Parkinson's disease programs also focus on neuroprotection and disease modification:

• GBA gene therapy: Partnerships targeting glucocerebrosidase (GBA) gene variants, a significant genetic risk factor for Parkinson's disease [14](https://pubmed.ncbi.nlm.nih.gov/32093318/)
• LRRK2 inhibitors: Leucine-rich repeat kinase 2 inhibitors for patients with LRRK2 mutations
• Mitochondrial protectants: Compounds targeting mitochondrial dysfunction in dopaminergic neurons

Levodopa Delivery Innovations

Building on the company's historic expertise in movement disorders, Bayer has explored novel levodopa delivery systems:

• Extended-release formulations: Improving the pharmacokinetic profile of levodopa
• Transdermal delivery: Providing continuous dopaminergic stimulation
• Combination therapies: Levodopa with novel adjunctive agents

Strategic Partnerships in Neuroscience

Bayer has established numerous strategic partnerships to access external innovation in neuroscience:

Eisai Co., Ltd

The partnership with Eisai represents Bayer's most significant neuroscience collaboration, focusing on Alzheimer's disease therapeutics. The elenbecestat partnership, though ultimately discontinued, demonstrated the company's commitment to collaborative drug development in neuroscience [15](https://www.bayer.com/en/partnerships/eisai).

Biotechnology Collaborations

• Biogen: Collaboration on tau immunotherapy programs
• Denali Therapeutics: Partnership on LRRK2 inhibitors for Parkinson's disease [16](https://www.denalitherapeutics.com/pipeline/)
• Voyager Therapeutics: Gene therapy programs for Parkinson's disease
• Neurocrine Biosciences: Movement disorder programs

Academic Partnerships

Bayer maintains research collaborations with leading academic institutions:

• University of Tübingen: Alzheimer's disease research
• University of Cambridge: Neurodegeneration research
• Massachusetts General Hospital: Clinical research in movement disorders
• Stanford University: Stem cell and gene therapy research

Acquisition History and Strategic Transactions

Bayer has pursued strategic acquisitions to build capabilities in key therapeutic areas:

| Year | Acquisition | Value | Strategic Focus |
|------|-------------|-------|-----------------|
| 2006 | Schering AG | €4.4 billion | Women's health, oncology, contrast agents |
| 2014 | Merck Consumer Care | $14.2 billion | Consumer health |
| 2016 | BlueRock Therapeutics | $599 million | Cell therapy, Parkinson's disease |
| 2020 | Asklepios BioPharmaceutical | $4 billion | Gene therapy |
| 2022 | Vivid Therapeutics | $2 billion | Radiopharmaceuticals |

The acquisition of BlueRock Therapeutics in 2016 was particularly significant for neuroscience, providing Bayer with a leading cell therapy platform for Parkinson's disease. BlueRock's cell replacement therapy, which involves transplantation of dopamine-producing neurons derived from pluripotent stem cells, represents a potentially curative approach for Parkinson's disease [17](https://www.bluerocktx.com/pipeline/).

The 2020 acquisition of Asklepios BioPharmaceutical (AskBio) gave Bayer a comprehensive gene therapy platform with applications across multiple therapeutic areas, including Parkinson's disease and other neurological conditions [18](https://www.bayer.com/en/investors/askbio).

Financial Performance and Market Position

Bayer's financial performance reflects its position as one of the world's leading pharmaceutical companies:

Revenue and Profitability

• 2025 Revenue: Approximately €44 billion
• Pharmaceutical Division: ~€18 billion (2025)
• Market Capitalization: ~€65 billion (2026)
• R&D Investment: ~€5 billion annually (approximately 12% of revenue)

• Xarelto (rivaroxaban): Oral anticoagulant, the company's best-selling drug
• Eylea (aflibercept): Anti-VEGF therapy for ophthalmology
• Nivolumab: Oncology partnership with Bristol-Myers Squibb
• Kerendia (finerenone): Novel cardiovascular drug

Stock Performance and Investor Relations

Bayer's shares are traded on the Frankfurt Stock Exchange (ETR: BAYN) and are a component of the DAX index. The company has undertaken significant shareholder returns programs, including dividend increases and share buybacks. The company's balance sheet remains investment-grade rated, providing flexibility for strategic investments in research and development [19](https://www.bayer.com/en/investors).

R&D Investment Strategy

Bayer invests approximately €5 billion annually in research and development, representing about 12% of total revenue. Within the pharmaceutical division, neuroscience represents a strategic priority area, though the company has faced challenges in delivering late-stage assets in the field. The company's R&D strategy emphasizes:

• External innovation: Partnerships, acquisitions, and licensing to complement internal capabilities
• Patient-centric development: Focusing on outcomes that matter to patients
• Digital transformation: Leveraging artificial intelligence and machine learning in drug discovery

Competitive Landscape

Bayer operates in a highly competitive pharmaceutical landscape, particularly in neuroscience:

Major Competitors in Neuroscience

• Roche/Genentech: Leading Alzheimer's disease pipeline with gantenerumab and crenezumab programs
• Biogen/Eisai: Approved Alzheimer's treatment Leqembi (lecanemab) and robust pipeline
• Eli Lilly: Donanemab in late-stage development and strong Alzheimer's pipeline
• AbbVie: Parkinson's disease programs and neuroscience portfolio
• Takeda: Japanese competitor with CNS portfolio and partnerships
• Novo Nordisk: Emerging player in neurodegeneration through GLP-1 programs

Competitive Advantages

Bayer's competitive position in neuroscience is supported by several factors:

• Global R&D network: Integrated research infrastructure spanning multiple continents
• Strategic partnerships: Access to external innovation through collaborations
• Manufacturing expertise: Strong capabilities in small molecule and biologics production
• Regulatory experience: Established relationships with regulatory authorities worldwide

Challenges

The company faces significant challenges in neuroscience:

• High failure rate: Alzheimer's and Parkinson's drug development has historically had high attrition
• Competitive landscape: Multiple large pharmaceutical companies pursuing similar targets
• Regulatory complexity: Novel mechanisms require extensive safety and efficacy data

Corporate Social Responsibility and Access to Medicine

Bayer maintains robust corporate social responsibility programs, including in neuroscience:

Patient Access Programs

• Patient assistance programs: Providing medications at reduced cost or free to eligible patients
• Clinical trial diversity initiatives: Expanding access to underrepresented populations
• Health education programs: Supporting disease awareness and early diagnosis

Global Health Initiatives

• World Health Organization partnerships: Contributing to global health goals
• Developing world access: Pricing strategies and distribution partnerships for low-income countries
• Healthcare infrastructure: Supporting capacity building in underserved regions

Environmental Sustainability

Bayer has committed to ambitious environmental goals, including:

• Carbon neutrality: Targeting net-zero emissions by 2030
• Sustainable sourcing: Ensuring responsible supply chain practices
• Water stewardship: Reducing water usage in manufacturing operations

Future Directions and Strategic Outlook

Bayer has articulated several strategic priorities for its neuroscience pipeline:

The company's long-term vision for neuroscience includes building a sustainable pipeline of disease-modifying therapies for neurodegenerative diseases, leveraging its global capabilities in research, development, and commercialization.

Pipeline Summary

| Program | Indication | Development Stage | Mechanism |
|---------|------------|-------------------|-----------|
| Elenbecestat | Alzheimer's disease | Discontinued (Phase 3) | BACE inhibition |
| Tau antibodies | Alzheimer's disease | Preclinical | Immunotherapy |
| Alpha-synuclein programs | Parkinson's disease | Discovery/Preclinical | Multiple mechanisms |
| Cell therapy (BlueRock) | Parkinson's disease | Phase 1/2 | Cell replacement |
| Gene therapy (AskBio) | Parkinson's disease | Preclinical | AAV gene delivery |
| LRRK2 inhibitors | Parkinson's disease | Discovery | Kinase inhibition |

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [BACE Inhibitors](/mechanisms/bace-inhibition)
• [Pharmaceutical Companies in Neurodegeneration](/companies/pharmaceutical-companies-neurodegeneration)
• [Gene Therapy for Parkinson's](/diseases/gene-therapy-parkinsons)
• [Tau Protein](/proteins/tau)

External Links

• [Bayer AG Official Website](https://www.bayer.com)
• [Bayer Pharmaceutical Pipeline](https://www.bayer.com/pipeline)
• [Bayer Innovation Strategy](https://www.bayer.com/en/innovation)
• [Bayer Investor Relations](https://www.bayer.com/en/investors)

References

<!-- expansion-work-done-2026-03-27 -->